DIPYRIDAMOLE INJECTION, USP 5 MG
DIPYRIDAMOLE : 5 MG · DIN 02244475 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is DIPYRIDAMOLE INJECTION, USP?
DIPYRIDAMOLE INJECTION, USP 5 MG contains DIPYRIDAMOLE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02244475, held by FRESENIUS KABI CANADA LTD, supplied as LIQUID for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 11-Sep-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DIPYRIDAMOLE INJECTION, USP used for?
To induce pharmacologic vasodilation for myocardial perfusion imaging.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02244475 |
|---|---|
| Brand name | DIPYRIDAMOLE INJECTION, USP |
| Generic / active ingredient | DIPYRIDAMOLE : 5 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 5 MG |
| Dosage form | LIQUID |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AC07 DIPYRIDAMOLE |
| AHFS class | 24:12.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Sep-2015 |
| Original market date | 2002-04-23 00:00:00 |
How is it administered?
0.142 mg/kg/min infused over 4 minutes. Dilute 1:1 with Dextrose 5%. Total dose >60 mg not recommended. Inject imaging agent within 5 minutes after infusion.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15 to 30°C). Protect from direct light and avoid freezing.
How is it supplied?
10 mL single-dose vials in packages of 10 vials.
Contraindications
Hypersensitivity to the drug or any ingredient; states of shock or collapse.
Warnings and precautions
May cause sudden death, cardiac arrest, and ECG change. Use only in clinical settings with appropriate monitoring. Risk of fatal/non-fatal MI, bronchospasm, and severe hypotension.
What can be used instead?
Other Canadian products sharing ATC code B01AC07 DIPYRIDAMOLE. 2 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PERSANTINE | 5 MG | SOLUTION | GLENWOOD GMBH PHARMAZEUTISCHE ERZEUGNISSE | MARKETED | DIN 00637734 |
| APO-DIPYRIDAMOLE | 100 MG | TABLET | APOTEX INC | CANCELLED PRE MARKET | DIN 02220571 |
| APO-DIPYRIDAMOLE | 25 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00895644 |
| APO-DIPYRIDAMOLE | 50 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00895652 |
| APO-DIPYRIDAMOLE | 75 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00895660 |
| APO-DIPYRIDAMOLE-SC TAB 25MG | 25 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00571237 |
| APO-DIPYRIDAMOLE-SC TAB 50MG | 50 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00571245 |
| APO-DIPYRIDAMOLE-SC TAB 75MG | 75 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00601845 |
| DIPYRIDAMOLE 25 TAB 25MG | 25 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00579580 |
| DIPYRIDAMOLE 50 TAB 50MG | 50 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00579572 |
Who else supplies DIPYRIDAMOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DIPYRIDAMOLE appears in 15 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.